ResearcherSouth Texas Accelerated Research TherapeuticsActive in the last 2 years

Drew Warren Rasco

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-6619-2854; OpenAlex author ID A5073134832. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 8

Papers, trials and grants by year

2026: 2 papers

Papers 2

A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancre… Last author DOI 10.1002/cncr.70343 ↗
Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". Last author DOI 10.1002/cncr.70510 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gayle Jameson · 2 shared papers, 2026 · strength 0.51
- Paper Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". DOI 10.1002/cncr.70510 ↗
- Paper A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic … DOI 10.1002/cncr.70343 ↗
Joshua D. Rabinowitz · 2 shared papers, 2026 · strength 0.51
- Paper Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". DOI 10.1002/cncr.70510 ↗
- Paper A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic … DOI 10.1002/cncr.70343 ↗
Erkut Hasan Borazanci · 2 shared papers, 2026 · strength 0.51
- Paper Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". DOI 10.1002/cncr.70510 ↗
- Paper A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic … DOI 10.1002/cncr.70343 ↗
Diana L. Hanna · 2 shared papers, 2026 · strength 0.51
- Paper Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". DOI 10.1002/cncr.70510 ↗
- Paper A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic … DOI 10.1002/cncr.70343 ↗
Daniel D. Von Hoff · 2 shared papers, 2026 · strength 0.51
- Paper Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". DOI 10.1002/cncr.70510 ↗
- Paper A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic … DOI 10.1002/cncr.70343 ↗
Derek Cridebring · 1 shared paper, 2026 · strength 0.22
- Paper A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic … DOI 10.1002/cncr.70343 ↗
Richard C. Frank · 1 shared paper, 2026 · strength 0.22
- Paper A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic … DOI 10.1002/cncr.70343 ↗
Angela Tatiana Alistar · 1 shared paper, 2026 · strength 0.22
- Paper A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic … DOI 10.1002/cncr.70343 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.